Citations

Mayo Clinic

Clear

2819 citation(s) found for "R, Liu".

A Witness to Being
Liu, Joy

Journal of Palliative Medicine | January 11, 2019 | Volume: 22 | Issue: 1 | Pages: 103-105

10.1089/jpm.2018.0277 | PMID 30633699 Get It

Book-Shaped Acellular Fibrocartilage Scaffold with Cell-loading Capability and Chondrogenic Inducibility for Tissue-Engineered Fibrocartilage and Bone–Tendon Healing
Chen, Can , Liu, Fei , Tang, Yifu , Zheng, Cheng , Chen, Yang , Li, Muzhi , Zhao, Chunfeng , Sun, Lun‐Quan , Lü, Hongbin , Zheng, Cheng , Chen, Yang , Li, Muzhi , Lu, Hongbin , Qu, Jin , Cao, Yong Bing , Hu, Jianzhong

ACS Applied Materials & Interfaces | January 9, 2019 | Volume: 11 | Issue: 3 | Pages: 2891-2907

10.1021/acsami.8b20563 | PMID 30620556 Get It

Effect of Biomaterial Electrical Charge on Bone Morphogenetic Protein-2-Induced In Vivo Bone Formation
Olthof, Maurits G.L. , Liu, Xifeng , Dadsetan, Mahrokh, Tryfonidou, Marianna A. , Yaszemski, Michael J. , Lu, Lichun , Kempen, Diederik H.R. , Dhert, Wouter J.A.

Tissue Engineering Part A | January 5, 2019 | Volume: 25 | Issue: 13-14 | Pages: 1037-1052

10.1089/ten.tea.2018.0140 | PMID 30612538 Get It

Biomaterials that act as both protein delivery vehicle and scaffold can improve the safety and efficacy of bone morphogenetic protein-2 (BMP-2) for clinical applications. However, the optimal scaffold characteristics are not known. The osteoinductive and osteoconductive capacity of a fixed electrically charged surface is thus far unexplored. Therefore, in this study, we aim to investigate the effect of different electrical states on BMP-2-induced bone formation in oligo[(polyethylene glycol) fumarate] (OPF) hydrogels. Neutral, negatively, or positively charged scaffolds were fabricated using unmodified OPF (neutral charge), sodium methacrylate crosslinked OPF (negative charge), or [2-(methacryloyloxy) ethyl] trimethylammonium chloride crosslinked OPF (positive charge), respectively. To allow investigation of surface charge for different BMP-2 release rates, three BMP-2 release profiles were generated by protein encapsulation into poly(lactic-co-glycolic acid) microspheres and/or adsorption on the OPF composite. Release of radiolabeled 125 I-BMP-2 was analyzed in vitro and in vivo and bone formation was assessed after 9 weeks of subcutaneous implantation in rats. Negatively charged OPF generated significantly more bone formation compared with neutral and positively charged OPF. This effect was seen for all three loading methods and subsequent BMP-2 release profiles. Along with charge modifications, a more sustained release of BMP-2 improved overall bone formation in OPF composites. Overall, this study clearly shows that negative charge enhances bone formation compared with neutral and positive charge in OPF composites. Impact Statement Biomaterials can play a dual role in bone regeneration: they enable local sustained delivery of growth factors, such as bone morphogenetic protein-2 (BMP-2), while they provide structural support as scaffold. By better imitating the properties of native bone tissue, scaffolds may be both osteoconductive and osteoinductive. The latter can be achieved by modifying the electrical charge of the surface. The present work uses tunable oligo[(polyethylene glycol) fumarate] hydrogel and demonstrates that negative charge enhances BMP-2-induced bone formation compared with neutral or positive charge. Altogether, this indicates that tissue-specific surface charge modifications of biomaterials hold great promise in the field of tissue regeneration.
Scrambler therapy for treatment of chemotherapy-induced peripheral neuropathy.
Weisbrod, Breanna L., Pachman, Deirdre R. , Seisler, Drew K., Barton, Debra L. , Fee-Schroeder, Kelliann C., Liu, Heshan , Loprinzi, Charles L. , Smith, Thomas J. , Lachance, Daniel Honore , Cheville, Andrea

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 9622-9622

10.1200/jco.2014.32.15_suppl.9622 Get It

The effect of SETD2 mutation (mts) on histone 3 lysine 36 tri-methylation (H3K36me3) and correlation with clinical outcome in patients (pts) with metastatic clear cell renal cell carcinoma (ccRCC) enrolled in COMPARZ.
D’Amelio, Anthony M., Hsieh, James J. , Souza, Paul L. de , Deen, Keith C., Langmuir, Peter, Liu, Yuan , Ho, Thai H. , Choueiri, Toni K. , Motzer, Robert J.

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 4583-4583

10.1200/jco.2014.32.15_suppl.4583 Get It

TBCRC 022: Phase II trial of neratinib for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer and brain metastases (BCBM).
Gelman, Rebecca , Krop, Ian E. , Melisko, Michelle , Agar, Nathalie Y.R. , Blackwell, Kimberly , Connolly, Roisín M. , Poznak, Catherine Van , Puhalla, Shannon, Ryabin, Nicole, Lawler, Elizabeth S, Ibrahim, Nuhad K. , Liu, Minetta C. , Agar, Nathalie Y R , Freedman, Rachel A. , Wefel, Jeffrey S. , Lowe, Alarice Cheng-Yi , Niravath, Polly Ann , Wolff, Antonio C. , Winer, Eric P. , Lin, Nancy U.

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 528-528

10.1200/jco.2014.32.15_suppl.528 Get It

Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial.
Sweeney, Christopher, Liu, Glenn , Jarrard, David Frasier, Eisenberger, Mario A. , Wong, Yu‐Ning, Hahn, Noah M. , Cooney, Matthew M. , Shevrin, Daniel H. , García, Jorge A. , DiPaola, Robert S. , Chen, Yu‐Hui , Carducci, Michael A. , Kohli, Manish , Vogelzang, Nicholas J. , Dreicer, Robert , Picus, Joel , Hussain, Maha

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: LBA2-LBA2

10.1200/jco.2014.32.15_suppl.lba2 Get It

Prognostic and predictive significance of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial.
Chapman, Judy‐Anne W., Burnell, Margot J., Levine, Mark N. , Whelan, Timothy J. , Albain, Kathy S. , Perez, Edith A. , Virk, Shakeel , O’Brien, Patti, Shepherd, Lois E. , Gelmon, Karen A. , Liu, Shuzhen , Pritchard, Kathleen I. , Rugo, Hope S. , Nielsen, Torsten O.

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 11019-11019

10.1200/jco.2014.32.15_suppl.11019 Get It

Phase I/II study of letrozole and sorafenib as first-line therapy of hormone-receptor positive (HR+) metastatic breast cancer (MBC).
Tan, Antoinette R. , Wong, Serena, Warren, Robert, Eng‐Wong, Jennifer , Liu, Minetta C. , Zelnak, Amelia, Shih, Weichung, Ganesan, Shridar , Grana, Generosa , Toppmeyer, Deborah , Lin, Yong , Isaacs, Claudine

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 531-531

10.1200/jco.2014.32.15_suppl.531 Get It